Alert on AMLX stock: Our scanners at TechStockMovers.com have found the following information on AMLX stock with the help of Tipranks.com...
Andrew Fein analyst at H.C. Wainwright reiterates coverage on Amylyx Pharmaceuticals, Inc. (AMLX) in the tech stock sector with a Buy rating. TipRanks.com has Fein rated as a 4.8 star analyst with a 50% return on investment and a 14.7% success rate. Fein has set a price target of $42.
TipRanks.com reports that Amylyx Pharmaceuticals, Inc. stock currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $36.40. The target pricing ranges from a high forecast of $42 down to a low forecast of $27. Amylyx Pharmaceuticals, Inc. (AMLX) stock's last closing price was $17.65 which would put the average price target at 106.23% upside.
In addition, TradingView.com issued a rating for AMLX over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on AMLX's stock.
Other analysts covering AMLX stock include:
Just a reminder, one resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals.
TipRanks.com tracks and measures the performance of over 50,000 financial experts.
The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance.
Get more from TipRanks.com here >>
When an analyst reiterates coverage on AMLX's stock, we will let you know. Please make sure you subscribe to our email newsletter to get timely alerts. Join thousands of other investors, you can always unsubscribe.
TechStockMovers.com keeps investors informed on a variety of tech stocks including communications equipment, IT Services, Semiconductors, Software, Technical hardware, storage and peripherals, artificial intelligence (AI), cybersecurity and more. (TSM) aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================
Andrew Fein analyst at H.C. Wainwright reiterates coverage on Amylyx Pharmaceuticals, Inc. (AMLX) in the tech stock sector with a Buy rating. TipRanks.com has Fein rated as a 4.8 star analyst with a 50% return on investment and a 14.7% success rate. Fein has set a price target of $42.
TipRanks.com reports that Amylyx Pharmaceuticals, Inc. stock currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $36.40. The target pricing ranges from a high forecast of $42 down to a low forecast of $27. Amylyx Pharmaceuticals, Inc. (AMLX) stock's last closing price was $17.65 which would put the average price target at 106.23% upside.
In addition, TradingView.com issued a rating for AMLX over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on AMLX's stock.
Other analysts covering AMLX stock include:
- Corinne Johnson of Goldman Sachs issued a Buy rating with the price target of $40 on 3 days ago
- Graig Suvannavejh of Mizuho Securities issued a Buy rating with the price target of $27 on 4 days ago
- Joel Beatty of Robert W. Baird issued a Buy rating with the price target of $37 on 1 month ago
- Neena Bitritto-Garg of Deutsche Bank issued a Buy rating with the price target of $36 on 2 months ago
Just a reminder, one resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals.
TipRanks.com tracks and measures the performance of over 50,000 financial experts.
The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance.
Get more from TipRanks.com here >>
When an analyst reiterates coverage on AMLX's stock, we will let you know. Please make sure you subscribe to our email newsletter to get timely alerts. Join thousands of other investors, you can always unsubscribe.
TechStockMovers.com keeps investors informed on a variety of tech stocks including communications equipment, IT Services, Semiconductors, Software, Technical hardware, storage and peripherals, artificial intelligence (AI), cybersecurity and more. (TSM) aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================
